Olhava, Edward J.

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 1,990

Targeting the NLRP3 inflammasome in inflammatory diseases

Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery

Inflammasome and immune disordersImmune Response and Inflammation

Cited by 1,885

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology

Epigenetics and DNA MethylationCancer-related gene regulation

Cited by 776

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood

Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research

Cited by 722

Erratum: Targeting the NLRP3 inflammasome in inflammatory diseases

Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery

Inflammasome and immune disordersImmune Response and Inflammation

Cited by 465